enGene Announces Preliminary Data Update from Pivotal LEGEND Trial in Bladder Cancer
enGene Holdings Inc. will host a conference call and webcast on November 11, 2025, at 8:00 a.m. ET to discuss preliminary data from the pivotal LEGEND trial, which evaluates its gene therapy candidate, detalimogene voraplasmid, in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. A slide deck will be available before the call, and a replay will be accessible on the company's website for one year.
enGene Holdings Inc., a clinical-stage, non-viral genetic medicines company, announced it will host a conference call and webcast on November 11, 2025, at 8:00 a.m. ET to discuss new preliminary data from the pivotal cohort of the ongoing LEGEND trial. The trial is evaluating detalimogene voraplasmid (previously EG-70), a non-viral gene therapy candidate, in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The company stated that a slide deck will be available prior to the call and a replay of the webcast will be accessible on its website for one year. Results from the pivotal cohort will be presented during the upcoming call. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110861491) on November 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
